Last reviewed · How we verify

Nicotine Transdermal Patch

University of Southern California · FDA-approved active Small molecule

Nicotine binds to nicotinic acetylcholine receptors in the central and peripheral nervous system, providing nicotine replacement to reduce withdrawal symptoms and cravings in tobacco users.

Nicotine binds to nicotinic acetylcholine receptors in the central and peripheral nervous system, providing nicotine replacement to reduce withdrawal symptoms and cravings in tobacco-dependent individuals. Used for Smoking cessation in nicotine-dependent individuals.

At a glance

Generic nameNicotine Transdermal Patch
Also known asHabitrol Transdermal patch (US), Nicotinell Transdermal patch (Germany), Nicotinelle, nicotinell, Nicotine
SponsorUniversity of Southern California
Drug classNicotinic acetylcholine receptor agonist
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaAddiction Medicine / Smoking Cessation
PhaseFDA-approved

Mechanism of action

The transdermal patch delivers nicotine through the skin at a controlled rate, maintaining steady-state plasma levels throughout the day. This activation of nicotinic acetylcholine receptors mimics the effects of smoked tobacco, reducing the severity of withdrawal symptoms such as irritability, anxiety, difficulty concentrating, and cravings. The patch formulation allows for gradual dose reduction over time to facilitate smoking cessation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results